Waiting on Medicago trial results
October 28, 2009 by leonardzehr · Leave a Comment
In a New Idea of Interest report on Medicago (TSX-V:MDG), Dundee Securities said that if Phase 1 results for its lead H5N1 avian vaccine are positive in December, the company could “establish a leading position in the global effort to find a superior vaccine-production technology.” Analyst David Martin rates the stock “buy (speculative risk)” but [...]
Listen to BioTuesdays 
